文献速递呼吸道感染

昂拉地韦治疗中国成人急性无并发症甲型流感的3期试验

Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2025-06-07

这项在中国68个中心开展的随机、双盲、安慰剂和奥司他韦对照3期试验纳入702例甲型流感感染意向治疗人群,评估昂拉地韦600mg每日一次口服5天的疗效与安全性。结果显示昂拉地韦组症状缓解时间显著短于安慰剂组,与奥司他韦组相似,安全性可接受。

要点

  • 昂拉地韦组不良事件发生率67%,腹泻49%但多为1-2级且自限。

核心结论

  • 昂拉地韦对成人急性无并发症甲型流感感染的疗效与奥司他韦相似,安全性可接受。
  • 在抗病毒药物敏感性下降的背景下,昂拉地韦可作为替代选择或联合用药候选。

研究设计与样本

  • 随机、双盲、多中心、安慰剂对照和奥司他韦对照的3期试验,在中国68个临床中心开展。
  • 按症状评分(≤11或≥12)分层,以2:1:1随机分配至昂拉地韦600mg每日一次、奥司他韦75mg每日两次或安慰剂,疗程5天。
  • 主要结局为意向治疗感染人群中昂拉地韦对比安慰剂的症状缓解时间。
  • 共筛选943例,随机750例,702例甲型流感阳性纳入意向治疗感染人群。

主要发现

  • 不良事件发生率:昂拉地韦组250/373(67%),安慰剂组104/189(55%),奥司他韦组89/188(47%)。
  • 腹泻发生率昂拉地韦组184例(49%),高于安慰剂组44例(23%)和奥司他韦组28例(15%),但多为1-2级,中位持续2天(IQR 1-3),无需药物治疗即缓解。

临床怎么用

  • 昂拉地韦600mg每日一次口服5天可作为成人急性无并发症甲型流感的替代抗病毒方案。
  • 用药前需快速甲型流感抗原检测阳性,并在症状出现48小时内启动治疗。
  • 需关注腹泻不良反应,但多为轻中度且自限,无需特殊处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Onradivir (ZSP1273) is a potent inhibitor of the PB2 subunit of influenza A virus (IAV) polymerase. Our previous, phase 2 clinical trial showed that a 600 mg regimen of onradivir initiated within 48 h of symptom onset can expedite the recovery of adult patients from acute, uncomplicated influenza. Here, we aimed to evaluate the safety and therapeutic efficacy of onradivir in a larger group with acute, uncomplicated influenza. METHODS: This randomised, double-blind, multicentre, placebo-controlled and oseltamivir-controlled, phase 3 trial was conducted at 68 clinical sites in China. Eligible participants were adults (aged 18-64 years) with an influenza-like illness who screened positive by rapid IAV antigen testing at the first clinical visit, and had a fever (axillary temperature ≥38·0°C) with at least one moderate systemic and one moderate respiratory symptom within 48 h of symptom onset. Patients were randomly assigned into three treatment groups, stratified by influenza symptom scores (≤11 or ≥12), in a 2:1:1 ratio by an interactive web response system, with each treatment lasting 5 days: 600 mg oral onradivir tablets once daily, 75 mg oral oseltamivir phosphate capsules twice daily, or oral placebo. The primary outcome was the efficacy of onradivir versus placebo in the time to alleviation of symptoms (TTAS), from treatment initiation to the remission of influenza symptoms, in the intention-to-treat infection (ITTI) population (ie, all participants who were randomly assigned and tested positive for IAV). The safety endpoints were the frequency and severity of adverse events in all participants who received treatment at least once. This trial is registered with ClinicalTrials.gov (NCT04683406) and is completed. This clinical trial was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (EC-2020-080[YW]-02). FINDINGS: Between May 12, 2022, and May 16, 2023, 943 patients were screened, of whom 750 met the inclusion criteria and were randomly assigned to a group. 48 had negative IAV tests, resulting in an ITTI population of 702 participants (413 [59%] men and 289 [41%] women; mean age 28·1 years [SD 9·7]): 349 in the onradivir group, 177 in the oseltamivir group, and 176 in the placebo group. The baseline viral load (mean 5·15 log10 copies per mL [SD 1·02]) and the total score of seven influenza symptoms at enrolment were similarly distributed among the groups. The median TTAS in the onradivir group was significantly shorter than that of placebo (38·83 h [95% CI 35·32-41·18] vs 63·35 h [55·48-68·48], difference -24·52 h, p<0·0001, HR 1·53 [95% CI 1·27-1·85]) and similar to that of the oseltamivir group (42·17 h [38·27-52·83], p=0·092, HR 1·12 [0·93-1·35]. Adverse events occurred in 250 (67%) of 373 in the onradivir group, 104 (55%) of 189 in the placebo group, and 89 (47%) of 188 in the oseltamivir group. Although the incidence of diarrhoea was higher in the onradivir group (184 [49%]) than in the placebo (44 [23%]) or oseltamivir (28 [15%]) groups, most incidences were grade 1 or 2, lasted a median of 2 days (IQR 1-3), and resolved without medication. INTERPRETATION: Onradivir has similar curative efficacy to oseltamivir for acute, uncomplicated influenza infections in adult patients, with an acceptable safety profile. At a time when reduced susceptibility to antiviral drugs is a growing concern, this study indicates that onradivir could be an alternative antiviral option or a candidate for use in combination with other antiviral agents for uncomplicated IAV infection. FUNDING: National Multidisciplinary Innovation Team Project of Traditional Chinese Medicine; National Natural Science Foundation of China; Guangdong Science and Technology Foundation; Major Project of Guangzhou National Laboratory; Guangdong Raynovent Biotechnology.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Yang Z, Zhan Y, Li Z, et al. Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial. Lancet Respir Med. 2025. PMID: 40489986. doi:10.1016/S2213-2600(25)00046-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。